GLP-TZ is a dual-acting peptide that activates both GIP and GLP-1 receptors, giving researchers a unique model for exploring weight regulation and glucose metabolism. This combination approach has led to striking findings in clinical studies, where tirzepatide produced some of the most significant results ever seen in metabolic research. Each vial represents a tool forged for exploring multi-pathway regulation of metabolism, energy, and appetite.
 
Research Outcomes in Studies:
In a 72-week obesity trial, subjects achieved average weight loss of 15–21%, depending on dose.
Studies reported reductions in HbA1c of up to 2.4%, highlighting strong glycemic control.
Improvements in cardiometabolic markers, including waist circumference and blood pressure.
 
Reference Guide
For deeper research frameworks and pathway explanations, visit The Forge Research Guide.

For laboratory research use only. Not for human or veterinary consumption. Not FDA evaluated.